No quarterly revenue total was found in PDS Biotechnology Corporation's SEC filings.
PDS Biotechnology Corporation (PDSB) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $5.6 million in cash and investments and $41,172 in total debt.
Revenue
—
Net income
$-9.75M
-3.4% vs year-ago quarter
Operating cash flow
$-2.79M
+69.3% vs year-ago quarter
Free cash flow
$-3.70M
+55.0% vs year-ago quarter
EPS
$-0.18
+14.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
55.97M
+20.0% vs year-ago quarter
Net cash
$5.56M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PDSB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1472091
- Former names
- Edge Therapeutics, Inc. (until Mar 18, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.5M | -$6.5M | -$6.7M | -$8.1M | -$7.6M |
| Net income | -$9.8M | -$7.3M | -$7.6M | -$9.0M | -$9.4M |
| Diluted EPS | -$0.18 | -$0.13 | -$0.15 | -$0.19 | -$0.21 |
| Operating cash flow | -$2.8M | -$4.4M | -$3.7M | -$5.9M | -$9.1M |
| Free cash flow | — | — | -$3.7M | -$5.9M | -$9.1M |
| Total assets | $8.8M | $24.7M | $30.5M | $34.7M | $40.5M |
| Total liabilities | $12.4M | $20.8M | $21.2M | $25.3M | $24.5M |
| Stockholders' equity | -$3.6M | $3.9M | $9.3M | $9.5M | $16.0M |
| Cash and investments | $5.6M | $21.7M | $26.7M | $26.2M | $31.9M |
| Total debt | $41,172 | $48,655 | $61,853 | $77,659 | $93,110 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 20, 2026 | Oct 18, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Other events
|
Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Agreement ended, Officer or director change, Regulation FD disclosure, Other events
|
Sep 14, 2026 | Sep 12, 2026 |
All 795 PDS Biotechnology Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.